Down 13%: More Bad Luck for Amarin Corporation plc

Shares of biotech company Amarin (NASDAQ: AMRN  ) , already down more than 70% in the last month, fell another 13% after it announced that the FDA has rescinded its SPA (Special Protocol Assessment) for Vascepa. The fledgling biotech not only faces competition from heavyweights like GlaxoSmithKline (NYSE: GSK  ) and AbbVie (NYSE: ABBV  ) , but has now also lost the opportunity to gain expanded approval for its drug, limiting its market potential.

For the full scoop on this story, health-care analyst Max Macaluso discusses the details and the outlook for Amarin in the following video.

Amazing growth stock to watch today
This incredible tech stock is growing twice as fast as Google and Facebook and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2706670, ~/Articles/ArticleHandler.aspx, 9/17/2014 1:36:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement